RIPK3 and neoplasm: To elucidate the impact of systemic defects in MPT-driven necrosis and necroptosis on HR+ mammary carcinogenesis, we subjected female WT, Ppif−/−, Ripk3−/−, and Mlkl−/− C57BL/6J mice of 6–9 weeks of age to M/D-driven mammary carcinogenesis according to established procedures [13, 23], and monitored them for tumor-free survival (TFS), as well as for a number of other parameters defining disease progression (Fig. 1A).